Water-soluble compound

• US 20070027129A1
• Filed: 02/23/2005
• Published: 02/01/2007
• Est. Priority Date: 10/31/2003
• Status: Abandoned Application

• Current Assignee: Technology Innovations, LLC
• Original Assignee: Technology Innovations, LLC
• Inventors: Goss, Kendrick, Tuszynski, Jack, Curry, Stephen, Greenwald, Howard
• Application Number:
  US11/064,247
• Publication Number:
  US 20070027129A1
• Time in Patent Office: Days
• US Class Current: 514/185
• CPC Class Codes: A61K 41/0004 Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61N 7/00 Ultrasound therapy lithotripsy A61B17/22, A61B17/225; massage using supersonic vibration A61H23/00 ; using ultrasound for introducing media into the body A61M37/0092

Abstract

A water-soluble magnetic anti-mitotic compound with a water-solubility of at least 100 micrograms per milliliter, a molecular weight of at least 150 grams per mole, a mitotic index factor of at least 10 percent, a positive magnetic susceptibility of at least 1,000×10⁻⁶ cgs, and a magnetic moment of at least 0.5 bohr magnetrons, wherein said compound is comprised of at least 7 carbon atoms and at least one inorganic atom with a positive magnetic susceptibility of at least 200×10⁻⁶ cgs.

Claims

1. A composition of matter comprised of a substrate comprised of a taxane, a magnetic moiety, and means for covalently binding said magnetic moiety to said taxane, thus producing a magnetic taxane.

2. The composition of matter as recited in claim 1, wherein said substrate has a mitotic index factor of at least about 20 percent.

3. The composition of matter as recited in claim 2, wherein said substrate has a mitotic index factor of at least about 30 percent.

4. The composition of matter as recited in claim 3, wherein said substrate has a mitotic index factor of at least about 50 percent.

5. The composition of matter as recited in claim 2, wherein said taxane is selected from the group consisting of a paclitaxel, a docetaxel, 10-desacetyl paclitaxel, and combinations thereof.

6. The composition of matter as recited in claim 1, wherein said magnetic moiety is paramagnetic.

7. The composition of matter as recited in claim 6, wherein said magnetic moiety is comprised of a nitroxide.

8. The composition of matter as recited in claim 1, wherein said magnetic moiety is comprised of a metallic atom.

9. The composition of matter as recited in claim 8, wherein said magnetic moiety is ferromagnetic.

10. The composition of matter as recited in claim 9, wherein said metallic atom has a positive magnetic susceptibility of at least 2×

10<sup>−

4</sup> cgs.

11. The composition of matter as recited in claim 10, wherein said metallic atom is iron.

12. The composition of matter as recited in claim 11, wherein said iron is iron (III).

13. The composition of matter as recited in claim 10, wherein said substrate has a positive magnetic susceptibility of at least 1×

10<sup>−

3</sup> cgs.

14. The composition of matter as recited in claim 13, wherein said magnetic moiety is a siderophore.

15. The composition of matter as recited in claim 14, wherein said siderophore is a hydroxamic acid.

16. The composition of matter as recited in claim 15, wherein said hydroxamic acid is a ferrichrome.

17. The composition of matter as recited in claim 15, wherein said hydroxamic acid is a ferricrocin.

18. The composition of matter as recited in claim 15, wherein said hydroxamic acid is a ferrioxamine.

19. A composition of matter comprised of a substrate comprised of a taxane, a magnetic moiety, and means for covalently binding said magnetic moiety to said taxane, thus producing a magnetic taxane wherein

a. said magnetic moiety is comprised of a iron atom with a positive magnetic susceptibility of at least 2×

10<sup>−

4</sup> cgs,

b. said substrate has appositive magnetic susceptibility of at least 1×

10<sup>−

3</sup> cgs, and

c. said magnetic moiety is further comprised of a ferrichrome.

20. The composition of matter as recited in claim 19, wherein said substrate has a mitotic index factor of at least about 20 percent.

21. The composition of matter as recited in claim 20, wherein said substrate has a mitotic index factor of at least about 30 percent.

22. The composition of matter as recited in claim 21, wherein said substrate has a mitotic index factor of at least about 50 percent.

23. A composition of matter comprised of a substrate comprised of a biologically active substrate and a magnetic moiety wherein:

a. said biologically active substrate is operatively configured to bind to a binding domain of a tubulin, wherein said tubulin is part of a microtubule,

b. said binding of said biologically active substrate to said binding domain alters the tread milling behavior of said microtubule such that said microtubule is stabilized,

c. said magnetic moiety is covalently bound to said biologically active substrate.

24. The composition of matter as recited in claim 23, wherein said binding domain is a vinca domain.

25. The composition of matter as recited in claim 24, wherein said biologically active substrate is selected from the group consisting of vinblastine, vincristine, vinorelbine, vinfluine, a cryptophycin, a halichondrins, a dolastatin, a hemiasterin, and combinations thereof.

26. The composition of matter as recited in claim 23, wherein said binding domain is a colchicines domain.

27. The composition of matter as recited in claim 26, wherein said biologically active substrate is selected from the group consisting of colchicine, a combretastatin, a methoxybenzene-sulphonamide, and combinations thereof.

28. The composition of matter as recited in claim 23, wherein said binding domain is a taxane domain.

29. The composition of matter as recited in claim 28, wherein said biologically active substrate is selected from the group consisting of a taxane, paclitaxel, docetaxel, an epothilone, and combinations thereof.